Table 4. Serum N-glycans differences between controls and diabetic patients with and without MS.
| CTR without MS | CTR with MS | T2DM- without MS | T2DM- with MS | T2DM+ without MS | T2DM+ with MS | |
|---|---|---|---|---|---|---|
| Mean(SD) | Mean(SD) | Mean(SD) | Mean(SD) | Mean(SD) | Mean(SD) | |
| P value | P value | P value | P value | P value | P value | |
| Males | N = 210 | N = 21 | N = 113 | N = 62 | N = 97 | N = 92 |
| Peaks (structure) | ||||||
| P1 (NGA2F) | 9.28 (2.58) | 10.21 (2.61) | 9.29 (2.66) | 10.04 (4.09) | 9.82 (3.16) | 9.63 (3.13) |
| P2 (NGA2FB) | 1.59 (0.5) | 1.6 (0.38) | 1.72 (0.54) | 1.85 (0.63) | 1.88 (0.81) | 1.86 (0.68) |
| P3 (NG1(6)A2F) | 6.2 (1.32) | 5.7 (0.88) | 5.38 (1.35) | 5.3 (1.45) | 5.3 (1.28) | 4.87 (1.38) |
| P<0.01 | P<0.001 | P<0.001 | P<0.001 | |||
| P4 (NG1(3)A2F) | 5.09 (0.83) | 4.9 (0.8) | 5.03 (1) | 4.68 (0.75) | 4.88 (0.8) | 4.67 (1.3) |
| P<0.05 | P<0.001 | |||||
| P5 (NA2) | 42.97 (4.06) | 43.31 (3.23) | 44.15 (4.51) | 43.75 (5.51) | 44.09 (4.69) | 44.77 (4.89) |
| P<0.01 | ||||||
| P6 (NA2F) | 18.11 (2.48) | 17.26 (2.52) | 17.78 (2.21) | 17.14 (2.62) | 17.62 (2.53) | 17.22 (2.65) |
| P7 (NA2FB) | 5.92 (1.32) | 5.6 (0.93) | 6.04 (1.41) | 6.02 (1.91) | 6.35 (1.76) | 6.22 (2.55) |
| P8 (NA3) | 6.57 (1.79) | 7.29 (1.99) | 6.52 (1.66) | 6.88 (1.82) | 6.03 (1.73) | 6.41 (1.7) |
| P9 (NA3F) | 2.84 (1.24) | 2.52 (1.26) | 2.74 (1.02) | 2.94 (1.02) | 2.74 (1.09) | 3.02 (1.02) |
| P10 (NA4) | 1.42 (0.49) | 1.62 (0.52) | 1.35 (0.43) | 1.41 (0.48) | 1.3 (0.43) | 1.33 (0.39) |
For each peak the mean and the SD are indicated. The reference group in each comparison is CTR without MS. For each comparison, the FDR-corrected p-value (q-value) is reported if <0.05.